Biocon Limited · NSE:BIOCON
Biocon — Q3 FY22 Earnings Presentation
24 slides from Biocon's earnings presentation, Jan 20, 2022
Slide 1: Exchange filing cover letter – Investor Presentation Q3 FY22
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com January 20, 2022 To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporat
Slide 2: Q3FY22 Investor Presentation
Q3FY22 Investor Presentation January 2022 B I O C O N L I M I T E D 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Biocon is a global biopharmaceutical company
Biocon is a global biopharmaceutical company that is leveraging its affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives. B I O C O N L I M I T E D 3
Slide 5: The Biocon Manifesto
The Biocon Manifesto accessibility affordability As a committed • Use our science, scale and • Focus on the kind of stakeholder of expertise to enhance access innovation that adds the to essential drugs for condition of affordability to the global health patients on the lowest rung accessibility of
Slide 6: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978- 2000- 2005- 2010- 2016- 2019 & 1999 2004 2009 2015 2018 Beyond An Transforming Building the Base Strategic Global Commercialized Poised for Enzymes into a Business and Alliance with Mylan Biosimilars for Global Impact Company Biopharma Expertise in fo
Slide 7: Biocon Today: Strategically poised for a strong global play
Biocon Today: Strategically poised for a strong global play Rs 7,360 Cr 12000+ Revenue* Total Employees* 1,200+ 25+ Patents cGMP approvals from International regulatory agencies 120+ Ranked 5 Countries where our Among Top 10 Global products are Biotech Employers by available Science magazine *FY21 6
Slide 8: Sustainability at Biocon
Sustainability at Biocon - Featured for the 1st time in ‘Dow Jones Received a ‘B’ score in Climate Change & Water Sustainability Emerging Markets Index’ for 2021 Security in CDP Score Report 2021 - Among Top 15 from India to be featured Philosophy of Unconditional Equity through… PATIENT EQUITY PEOP
Slide 9: Business Segments
Business Segments 8 B I O C O N L I M I T E D 8
Slide 10: Growth Verticals: Aligned With Shifting Paradigms
Growth Verticals: Aligned With Shifting Paradigms From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally. Ensuring Expanding Pushing Partnering to access through access through scientific deliver
Slide 11: Generics: Investing in capacities & capabilities for future growth
Generics: Investing in capacities & capabilities for future growth Differentiated API business Growing Formulations Footprint Investments for future growth • 5 state-of-the-art facilities across Bangalore, • Oral solids (potent & non-potent), parenteral & • Expanding our R&D capabilities for Hyderab
Slide 12: Generics: Q3 FY22
Generics: Q3 FY22 KEY HIGHLIGHTS Q3 FY22 Q3 FY21 Revenue growth due to launch of Everolimus in the US & uptake in Revenue API business ₹607Cr ₹567Cr Continued pricing pressure, higher RM/solvent & logistics cost 7% YoY increase Partnered with Tabuk pharmaceuticals to commercialize speciality product
Slide 13: Biosimilars: Fully integrated global player in an attractive market
Biosimilars: Fully integrated global player in an attractive market Product Status Therapeutic Commercialized several biosimilars in Areas Molecule US Dev. Markets: ex-US MoW5 developed and emerging markets Pegfilgrastim1 Europe, CANZ Trastuzumab1 Europe, CANZ Oncology Robust pipeline across multipl
Slide 14: Entering adjacencies in communicable disease: infectious disease antibodies and vaccines
Entering adjacencies in communicable disease: infectious disease antibodies and vaccines Key Commercial Products Recent Collaborations 50,000+ lives impacted Continued portfolio expansion 13 B I O C O N L I M I T E D 13
Slide 15: Key terms of alliance with SILS
Key terms of alliance with SILS 1 2 3 Commercialization Committed revenue Access to 100m doses rights of the SILS stream and related of vaccines annually for portfolio for global margins from 15 years markets H2 FY23 ~15% stake in BBL at a post-money valuation of ~$4.9bn Alliance to commercialize SI
Slide 16: Biosimilars: Q3 FY22
Biosimilars: Q3 FY22 KEY HIGHLIGHTS Q3 FY22 Q3 FY21 Strong performance of bGlargine in US evidenced by several Revenue commercial arrangements (e.g., ESI & Prime formulary listing) ₹981Cr ₹769Cr Robust growth in Biocon Biologics led commercial franchise in 28% YoY increase emerging markets Core EBIT
Slide 17: Novel Molecules: Pushing scientific boundaries to deliver impactful innovations
Novel Molecules: Pushing scientific boundaries to deliver impactful innovations Disease Area Asset Current Progress • Phase I multiple ascending dose studies in Type 1 DM patients ongoing in Germany; in Insulin Tregopil- a first-in-class oral, prandial partnership with US-based Juvenile Diabetes Res
Slide 18: Novels: Q3 FY22
Novels: Q3 FY22 KEY HIGHLIGHTS On track to initiate a pivotal study on Itolizumab in first-line acute GVHD* in early 2022 Part B of Phase 1b EQUALISE study for SLE / LN** expanded to clinical centers in India Bicara# completed enrolment in dose finding part of Phase 1 trial for its lead program, BCA
Slide 19: Research Services (Syngene)
Research Services (Syngene) Offering integrated research, development & manufacturing services for small & large molecules, antibody-drug conjugates & oligonucleotides backed by best-in-class bioinformatic services World-class R&D and manufacturing infrastructure spread over 2 million square feet Au
Slide 20: Research Services: Q3 FY22
Research Services: Q3 FY22 KEY HIGHLIGHTS Q3 FY22 Q3 FY21 Revenue Discovery & Dedicated Centers were growth drivers in Q3 ₹641Cr ₹585Cr 10% YoY increase Development & Manufacturing Services delivered sustained performances in Q3 PBT Extension and expansion of collaboration with Amgen until 2026; to
Slide 21: Financial Highlights
Financial Highlights 20 B I O C O N L I M I T E D 20
Slide 22: Annual Financial Highlights
Annual Financial Highlights FY21 FY20 Biosimilars +21% | Research Services Revenue +13% ₹7,360Cr ₹6,462Cr +9% | Generics +6% Core EBITDA1 +15% ₹2,430Cr ₹2,108Cr Forex loss of ₹9Cr in FY21 vs ₹65Cr of Forex gain in FY20 % margin 33% 33% Gross R&D spends at ₹627Cr in FY21 EBITDA +8% ₹1,907Cr ₹1,765Cr
Slide 23: Financial Highlights: Q3 FY22
Financial Highlights: Q3 FY22 Q3 FY22 Q3 FY21 Biosimilars +28% | Research Services Revenue +18% ₹2,223Cr ₹1,885Cr +10% | Generics 7% Mark-to-market loss on Adagio Core EBITDA* +23% ₹715Cr ₹581Cr investment of ₹77Cr % margin 33% 31% Forex Gain of ₹19Cr vs ₹6Cr in Q3 FY21 EBITDA +25% ₹537Cr ₹428Cr Gro
Slide 24: Thank You
Thank You INVESTOR RELATIONS CONTACT: Aishwarya Sitharam, Biocon Limited Tel: +91 93236 48143 Email: aishwarya.sitharam@biocon.com Nikunj Mall, Biocon Biologics Limited Tel : +91 998 777 4078 Email: nikunj.mall@biocon.com 23 B I O C O N L I M I T E D 23